Total Payments
$471,614
2024 Payments
$38,206
Companies
31
Transactions
718
Medicare Patients
4,721
Medicare Billing
$419,653
Payment Breakdown by Category
Consulting$348,279 (73.8%)
Other$75,230 (16.0%)
Food & Beverage$20,773 (4.4%)
Travel$15,686 (3.3%)
Research$11,633 (2.5%)
Education$13.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $348,279 | 225 | 73.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,830 | 30 | 14.2% |
| Food and Beverage | $20,773 | 364 | 4.4% |
| Travel and Lodging | $15,686 | 80 | 3.3% |
| Unspecified | $11,633 | 17 | 2.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,400 | 1 | 1.8% |
| Education | $13.89 | 1 | 0.0% |
Payments by Type
General
$459,982
701 transactions
Research
$11,633
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $239,179 | 344 | $0 (2024) |
| CVRx, Inc. | $75,010 | 43 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $53,293 | 46 | $0 (2024) |
| LivaNova USA, Inc. | $42,701 | 51 | $0 (2023) |
| Medtronic Vascular, Inc. | $20,076 | 54 | $0 (2020) |
| Lilly USA, LLC | $15,125 | 11 | $0 (2024) |
| Medtronic, Inc. | $14,257 | 36 | $0 (2024) |
| Boston Scientific Corporation | $5,576 | 10 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,941 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,348 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,206 | 76 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14,422) |
| 2023 | $49,466 | 87 | Boehringer Ingelheim Pharmaceuticals, Inc. ($25,896) |
| 2022 | $53,122 | 85 | LivaNova USA, Inc. ($13,160) |
| 2021 | $25,939 | 46 | LivaNova USA, Inc. ($12,460) |
| 2020 | $20,198 | 26 | LivaNova USA, Inc. ($11,221) |
| 2019 | $105,599 | 134 | Abbott Laboratories ($77,615) |
| 2018 | $111,489 | 138 | Abbott Laboratories ($93,753) |
| 2017 | $67,596 | 126 | Abbott Laboratories ($48,591) |
All Payment Transactions
718 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | CVRx, Inc. | Barostim Neo System (Device) | Consulting Fee | Cash or cash equivalent | $6,125.00 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $86.34 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/25/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: Heart Failure | ||||||
| 10/18/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: DIABETES | ||||||
| 10/10/2024 | Medtronic, Inc. | REVEAL LINQ (Device) | Food and Beverage | In-kind items and services | $79.62 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 10/08/2024 | Medtronic, Inc. | ADAPTA (Device) | — | Cash or cash equivalent | $265.00 | Research |
| Study: FIRE-HFpEF • Category: Pacemakers | ||||||
| 10/06/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $3.31 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Travel and Lodging | Cash or cash equivalent | $647.52 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $156.38 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $62.79 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $61.85 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $57.80 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $51.28 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $46.62 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $41.22 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/04/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $31.87 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: DIABETES | ||||||
| 09/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: DIABETES | ||||||
| 09/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $35.40 | General |
| Category: DIABETES | ||||||
| 08/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $120.07 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| FIRE-HFpEF | Medtronic, Inc. | $7,950 | 10 |
| PSR-CVG | Medtronic, Inc. | $2,633 | 4 |
| REVAMP | Medtronic Vascular, Inc. | $1,050 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 886 | 1,158 | $222,813 | $69,809 |
| 2022 | 19 | 973 | 1,224 | $230,968 | $70,805 |
| 2021 | 23 | 1,380 | 1,900 | $396,265 | $130,017 |
| 2020 | 22 | 1,482 | 2,110 | $432,937 | $149,023 |
Total Patients
4,721
Total Services
6,392
Medicare Billing
$419,653
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 152 | 226 | $60,520 | $20,408 | 33.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 53 | 137 | $35,346 | $12,417 | 35.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 44 | $22,044 | $5,811 | 26.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 84 | $15,036 | $5,235 | 34.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 89 | 89 | $16,287 | $4,534 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $11,733 | $3,279 | 27.9% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 37 | 37 | $10,175 | $3,030 | 29.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 57 | 57 | $10,431 | $2,593 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 39 | $7,162 | $2,327 | 32.5% |
| 93750 | Evaluation of lower heart chamber assist device | Facility | 2023 | 29 | 71 | $8,662 | $2,209 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 24 | $4,704 | $1,762 | 37.4% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 19 | 19 | $5,187 | $1,607 | 31.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $4,464 | $1,334 | 29.9% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 39 | 43 | $2,752 | $831.58 | 30.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $2,340 | $768.10 | 32.8% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 37 | 37 | $1,702 | $504.69 | 29.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 17 | 17 | $935.00 | $263.68 | 28.2% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 71 | 74 | $592.00 | $176.41 | 29.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 27 | 29 | $609.00 | $165.47 | 27.2% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 26 | 27 | $486.00 | $151.47 | 31.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 16 | $656.00 | $144.95 | 22.1% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 15 | 15 | $450.00 | $136.20 | 30.3% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 18 | 18 | $540.00 | $120.74 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 229 | 297 | $78,705 | $24,360 | 31.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 61 | 171 | $44,118 | $13,674 | 31.0% |
About Dr. Eugene Chung, M.D
Dr. Eugene Chung, M.D is a Cardiovascular Disease healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1003893926.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eugene Chung, M.D has received a total of $471,614 in payments from pharmaceutical and medical device companies, with $38,206 received in 2024. These payments were reported across 718 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($348,279).
As a Medicare-enrolled provider, Chung has provided services to 4,721 Medicare beneficiaries, totaling 6,392 services with total Medicare billing of $419,653. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Cincinnati, OH
- Active Since 12/30/2005
- Last Updated 10/24/2020
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1003893926
Products in Payments
- CardioMEMS HF System (Device) $217,986
- Barostim Neo System (Device) $75,010
- JARDIANCE (Drug) $68,418
- VNS - Vitaria (Device) $29,100
- VNS Therapy (Device) $13,601
- MITRACLIP (Device) $10,133
- ADAPTA (Device) $7,950
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $7,821
- GENERAL THERAPIES (Device) $3,500
- Micra (Device) $2,048
- Adapta (Device) $1,050
- GENERAL THERAPIES (Device) $1,010
- CARDIOMEMS (Device) $864.60
- GENERAL - THERAPIES (Device) $787.50
- REVEAL LINQ (Device) $725.86
- MICRA (Device) $696.11
- HeartMate 3 Left Ventricular Dev (Device) $660.55
- Reveal LINQ (Device) $419.68
- ENTRESTO (Drug) $348.68
- Product in Development (Device) $290.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Cincinnati
Timothy Henry, Md, MD
Cardiovascular Disease — Payments: $731,232
Cardiovascular Disease $731,232
Eli Roth, Md, MD
Cardiovascular Disease — Payments: $371,143
Cardiovascular Disease $371,143
Santiago Garcia, Md, MD
Cardiovascular Disease — Payments: $308,252
Cardiovascular Disease $308,252
Dr. Kamal Shemisa, Md, MD
Cardiovascular Disease — Payments: $290,400
Cardiovascular Disease $290,400
Joseph Choo, M.d, M.D
Cardiovascular Disease — Payments: $274,686
Cardiovascular Disease $274,686
John Corl, Md, MD
Cardiovascular Disease — Payments: $268,780
Cardiovascular Disease $268,780